Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing.

Pretreatment with Astragaloside VI (AS-VI) at 1 μM increases EGFR activation in HaCaT cells. Astragaloside VI, a major intestinal metabolite of astragalosides, exerts the strongest EGFR activation. In HaCaT cells, the positive control, EGF expectedly results in 1.5±0.03-fold increase in cell proliferation, compared to the control. Astragaloside VI at the indicated concentrations also significantly promots cell proliferation in both HaCaT and HDF cells^[1]. Astragaloside VI promotes neural stem cell proliferation and enhances neurological function recovery in transient cerebral ischemic injury via activating EGFR/MAPK signaling cascades^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Astragaloside VI improves wound healing, compared to the control. In the simple noninfected wound model, wound healing in mice is accelerated by Astragaloside VI, where in the time required for wound closure is shortened by approximately 2-4 days, compared to that in the control group. Topical treatment with Astragaloside VI reduces the volume of pus produced, compared to the control group. Astragaloside VI treated wounds show an accelerated rate of healing, compared to the control and vaseline groups. By day 22, the Astragaloside VI -treated wounds fully close, whereas the blank and vaseline-treated wounds do not fully close until day 26. Angiogenesis is a crucial step in the formation of granulation tissue and wound healing. Astragaloside VI increases blood vessel formation in both the non-infected and infected wound models^[1]. Astragaloside VI could effectively activate EGFR/MAPK signaling cascades, promote NSCs proliferation and neurogenesis in transient cerebral ischemic brains, and improve the repair of neurological functions in post-ischemic stroke rats^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

947.11

C₄₇H₇₈O₁₉

84687-45-6

Room temperature in continental US; may vary elsewhere.

DMSO : 100 mg/mL (105.58 mM; Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

  Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (2.64 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

• 2.

  请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

  Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (2.64 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
• 3.

  请依序添加每种溶剂： 10% DMSO    90% corn oil

  Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (2.64 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

• [1]. Lee SY, et al. Astragaloside VI and cycloastragenol-6-O-beta-D-glucoside promote wound healing in vitro and in vivo. Phytomedicine. 2018 Jan 1;38:183-191.

  [2]. Chen X, et al. Astragaloside VI Promotes Neural Stem Cell Proliferation and Enhances Neurological Function Recovery in Transient Cerebral Ischemic Injury via Activating EGFR/MAPK Signaling Cascades. Mol Neurobiol. 2018 Aug 7.